Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Therapeutics Acquisition Corp is a shell companies business based in the US. Therapeutics Acquisition shares (RACA) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$10.32|
|52-week range||$9.81 - $17.00|
|50-day moving average||$10.24|
|200-day moving average||$11.99|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||16.09%|
|3 months (2021-05-05)||3.10%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||-9999999%|
|Market capitalisation||$179.1 million|
TTM: trailing 12 months
There are currently 366,071 Therapeutics Acquisition shares held short by investors – that's known as Therapeutics Acquisition's "short interest". This figure is 0.8% down from 368,894 last month.
There are a few different ways that this level of interest in shorting Therapeutics Acquisition shares can be evaluated.
Therapeutics Acquisition's "short interest ratio" (SIR) is the quantity of Therapeutics Acquisition shares currently shorted divided by the average quantity of Therapeutics Acquisition shares traded daily (recently around 10914.460345856). Therapeutics Acquisition's SIR currently stands at 33.54. In other words for every 100,000 Therapeutics Acquisition shares traded daily on the market, roughly 33540 shares are currently held short.
However Therapeutics Acquisition's short interest can also be evaluated against the total number of Therapeutics Acquisition shares, or, against the total number of tradable Therapeutics Acquisition shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Therapeutics Acquisition's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Therapeutics Acquisition shares in existence, roughly 20 shares are currently held short) or 0.0562% of the tradable shares (for every 100,000 tradable Therapeutics Acquisition shares, roughly 56 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Therapeutics Acquisition.
Find out more about how you can short Therapeutics Acquisition stock.
We're not expecting Therapeutics Acquisition to pay a dividend over the next 12 months.
Therapeutics Acquisition Corp. , doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts. .
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.